Industrifonden leads investment in InDex

The deal was led by Industrifonden, which invested SEK 40m, while existing shareholders provided the remaining SEK 35m. SEB Venture Capital made its initial investment in the company in 2003.

Funding will support a phase-III study of the drug Kappaproct, which the company has developed, with the aim of clearing it for market use. If successful, the drug is looking to launch on the market within two years.

InDex Pharmaceuticals is based in Stockholm and develops DIMS drugs to treat diseases within a variety of therapeutic areas, including inflammation and cancer.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Viktor Lundvall on +44 20 7004 7476 or viktor.lundvall@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Early-stage
• Sweden